The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks.
Country United States of America
Visit trial
Status
Recruiting
Results Published
No
Start date
17 December 2020
End date
01 December 2022
Phase
Phase II
Design
Blinded
Type
Interventional
Generation
First
Participants
30
Sex
All
Age
18- 65
Therapy
No
Trial Details
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.Trial Number NCT04177706
Sponsors & Collaborators
Medical University of South CarolinaThe Medical University of South Carolina (MUSC) partnered with MAPS to create a psychedelic research centre to study the therapeutic effects of psychedelic drugs on mental illness.
National Institute on Drug Abuse
This company doesn't have a full profile yet, it is linked to a clinical trial.